MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of David A. McDonald and Martin J. Emerson to its Board of Directors, effective February 24, 2026. The appointments strengthen the Company’s board with complementary expertise in public company leadership, capital markets, and medical device commercialization. “These appointments reflect our cont ...

MINNEAPOLIS, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced that it will release financial results for the fourth quarter and full year 2025 on March 10, 2026. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. To access the live webcast, please visit the Investors page of the Nuwellis we ...

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - TechCreate Group Ltd. (TCGL) is up 99% at $205.71 - VivoSim Labs, Inc. (VIVS) is up 74% at $2.96 - La Rosa Holdings Corp. (LRHC) is up 55% at $4.66 - Sandisk Corporation (SNDK) is up 23% at $668.13 - Springview Holdings Ltd (SPHL) is up 19% at $4.76 - BUUU Group Limited (BUUU) is up 16% at $10.86 - Deckers Outdoor Corporation (DECK) is up 11% at $111.64 - Lumentum Holdings Inc. (LITE) is up 10% at $419.58 - Chanson International Holding (CHSN) is up 10% at $2.15 - Century Therapeutics, Inc. (IPSC) is up 9% at $2.20 [3] Premarket Losers - Kaixin Holdings (KXIN) is down 43% at $5.70 - Brand Engagement Network, Inc. (BNAI) is down 32% at $35.56 - PennyMac Financial Services, Inc. (PFSI) is down 21% at $117.50 - Schneider National, Inc. (SNDR) is down 19% at $24.05 - Moolec Science SA (MLEC) is down 19% at $5.23 - Nuwellis, Inc. (NUWE) is down 18% at $3.43 - Digital Currency X Technology Inc. (DCX) is down 16% at $3.44 - Serina Therapeutics, Inc. (SER) is down 15% at $3.03 - Namib Minerals (NAMM) is down 11% at $5.00 - ZeroStack Corp. (ZSTK) is down 6% at $11.00 [4]

Core Insights - Nuwellis, Inc. has appointed Carisa Schultz as Chief Financial Officer, effective February 2, 2026, to enhance its financial leadership in the medical technology sector focused on precision cardiorenal care [1][4]. Company Overview - Nuwellis, Inc. is a medical technology company that develops precision fluid management technologies aimed at improving patient care across the cardiorenal continuum, addressing both acute and chronic conditions [4]. - The company's product portfolio includes both commercially available and development-stage technologies that focus on safety, precision, and scalability for various patient populations [4]. Leadership Experience - Carisa Schultz has extensive experience in healthcare finance, having served as Vice President of Finance at NeueHealth, where she led enterprise finance, treasury, and corporate development [2]. - Schultz's background includes roles at Boston Scientific and various leadership positions in public and private healthcare organizations, along with experience in Big Four public accounting [3]. Product Highlight - The Aquadex SmartFlow® System is designed to remove excess fluid from patients suffering from hypervolemia, with indications for both temporary and extended use in adult and pediatric patients [5].

Core Viewpoint - Nuwellis, Inc. has announced a securities purchase agreement for a private placement of shares and warrants, aiming to raise approximately $5 million to support its operations in precision cardiorenal care [1][3]. Group 1: Private Placement Details - The company will sell 994,537 shares of common stock at an effective offering price of $3.09 per share, along with warrants to purchase 1,989,074 additional shares [1]. - The warrants will have an exercise price of $2.84 per share, exercisable immediately upon issuance, and will expire five years after a resale registration statement becomes effective [1]. Group 2: Warrant Inducement Agreement - Nuwellis has entered into a warrant inducement agreement with an investor to immediately exercise certain existing warrants at a reduced exercise price of $3.09, allowing the purchase of 623,585 shares [2]. - In exchange for the immediate exercise, the company will issue new unregistered warrants for an additional 1,247,170 shares at the same exercise price of $2.84, also expiring five years after the effective registration statement [2]. Group 3: Financial Proceeds and Closing - The gross proceeds from both the private placement and the warrant inducement are expected to be around $5 million before deducting fees and expenses, with the closing anticipated on or about January 30, 2026 [3]. - Ladenburg Thalmann & Co. Inc. is acting as the sole placement agent for these transactions [3]. Group 4: Company Overview - Nuwellis, Inc. is focused on advancing precision fluid management technologies for cardiorenal conditions, developing solutions for patient care through monitoring and therapy [6]. - The company is headquartered in Minneapolis, Minnesota, and aims to support clinical decision-making across various care settings [6][7]. Group 5: Product Information - The Aquadex SmartFlow system is a key product that provides therapy for patients with hypervolemia, indicated for both temporary and extended use in specific patient populations [9].

Core Viewpoint - Nuwellis, Inc. has entered into a Securities Purchase Agreement to acquire Rendiatech Ltd., enhancing its capabilities in real-time kidney function monitoring and expanding its cardiorenal platform [1][2]. Group 1: Transaction Details - The acquisition of Rendiatech is expected to close upon meeting customary closing conditions, positioning Nuwellis to broaden its portfolio into real-time renal diagnostics [1][5]. - The transaction has been approved by the boards of directors of both Nuwellis and Rendiatech [5]. Group 2: Strategic Implications - This acquisition represents a strategic move for Nuwellis, allowing the company to extend its capabilities beyond therapeutic fluid management into real-time renal monitoring, which aligns with its long-term vision [2][4]. - Nuwellis plans to leverage its existing commercial infrastructure and clinical relationships to integrate Rendiatech's technology effectively [4]. Group 3: Technology Overview - Rendiatech's Clarity™ system offers automated, continuous renal monitoring through precise urine-output measurement, aiming to replace manual collection methods [3][9]. - The addition of the Clarity system is expected to lay the groundwork for future advancements in urine-based analytics and comprehensive kidney function assessment [3].

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - Murano Global Investments Plc (MRNO) is up 146% at $3.35 [3] - Kustom Entertainment, Inc. (KUST) is up 34% at $2.84 [3] - Ainos, Inc. (AIMD) is up 34% at $2.32 [3] - Stride, Inc. (LRN) is up 29% at $94.10 [3] - Shuttle Pharmaceuticals Holdings, Inc. (SHPH) is up 18% at $2.40 [3] - Battalion Oil Corporation (BATL) is up 16% at $3.83 [3] - C3.ai, Inc. (AI) is up 15% at $14.58 [3] - Lantronix, Inc. (LTRX) is up 14% at $7.87 [3] - Nextpower Inc. (NXT) is up 13% at $120.00 [3] - High Roller Technologies, Inc. (ROLR) is up 7% at $7.56 [3] Premarket Losers - Flora Growth Corp. (FLGC) is down 34% at $7.20 [4] - TEN Holdings, Inc. (XHLD) is down 29% at $2.47 [4] - Global Interactive Technologies, Inc. (GITS) is down 22% at $3.25 [4] - 5E Advanced Materials, Inc. (FEAM) is down 15% at $2.70 [4] - Vyome Holdings, Inc. (HIND) is down 14% at $2.79 [4] - Altimmune, Inc. (ALT) is down 11% at $5.48 [4] - BiomX Inc. (PHGE) is down 10% at $6.22 [4] - Qorvo, Inc. (QRVO) is down 9% at $74.94 [4] - Nuwellis, Inc. (NUWE) is down 9% at $3.45 [4] - Brenmiller Energy Ltd (BNRG) is down 9% at $2.90 [4]

Core Insights - Nuwellis Inc's stock has experienced a significant surge, increasing over 100% in pre-market trading and remaining up around 85% shortly after the market opened, driven by investor interest in its unique healthcare narrative involving patents and board changes [1] Group 1: Boardroom Changes - Nuwellis recently announced a major board overhaul, with three long-serving directors resigning and two new directors with experience in scaling medical technology companies joining the board, indicating potential for faster execution and strategic interest [2] - The streamlining of the board is often interpreted by microcap traders as a sign that significant developments may be forthcoming [2] Group 2: Intellectual Property Developments - The stock's momentum is bolstered by a new patent issued for the Vivian™ Pediatric CRRT System, enhancing the company's intellectual property in the niche market of infant blood filtration, which is characterized by high margins and significant regulatory barriers [3] - The importance of niche intellectual property in healthcare can be pivotal, potentially attracting acquisition interest from larger players [3] Group 3: Market Dynamics - Nuwellis operates with a very limited float and liquidity, making it a prime candidate for momentum trading, as evidenced by the stock's dramatic pre-market rise and sustained gains [4] - The current market interest suggests that a microcap company may have established a defensible position in the overlooked area of infant healthcare, capturing the attention of investors [5]

Core Viewpoint - Nuwellis, Inc. has appointed Katharyn Field and Mika Grasso to its board of directors, effective January 21, 2026, while three members resigned from the board, with no disagreements reported [1][4][5]. Group 1: Board Appointments - Katharyn Field is the CEO of ISpecimen Inc. and has held various leadership roles in other companies, including Halo Collective and Marimed Inc. She holds an MBA from Columbia Business School and a BA from Stanford University [2]. - Mika Grasso is an Investment Manager at a private family office with prior experience at Zions Capital Markets, Paulson Investment Company, Goldman Sachs, and Power Systems Management. He holds an MS in Finance and a BS in Business Administration from the University of Colorado Boulder [3]. Group 2: Board Resignations - Dave McDonald, Mike McCormick, and Dr. Maria Costanzo resigned from the board effective January 21, 2026, with the company confirming that these resignations were not due to any disagreements regarding operations or policies [4][5]. Group 3: Company Overview - Nuwellis, Inc. is a medical technology company focused on precision fluid management technologies for cardiorenal care, developing solutions for both acute and chronic care settings [6]. - The company's portfolio includes technologies addressing complex cardiorenal conditions, emphasizing safety, precision, and scalability [6].

Core Insights - Nuwellis, Inc. has received a new U.S. patent for advanced safety mechanisms in blood return line clamps used in extracorporeal blood filtration systems, enhancing its pediatric intellectual property portfolio [1][3][4] Group 1: Patent Issuance - The newly issued patent focuses on safety innovations aimed at improving blood flow control reliability in extracorporeal circuits, particularly for pediatric applications where precision and safety are crucial [2][3] - This patent follows a Notice of Allowance and supports the development of the Vivian™ Pediatric Continuous Renal Replacement Therapy (CRRT) System [3][4] Group 2: Company Commitment and Strategy - The CEO of Nuwellis emphasized that each issued patent signifies progress in building a strong foundation of protected innovation, reinforcing the company's commitment to engineering precision and safety for vulnerable patient populations [4] - The patent contributes to Nuwellis' expanding intellectual property portfolio, supporting its pediatric development roadmap and broader cardio-renal strategy [4][6] Group 3: Product Overview - The Vivian system is designed specifically for neonates and children, featuring integrated sensors for real-time monitoring and offering multiple therapies on a single platform [9] - The system targets an extracorporeal blood volume of 29–67 mL and is developed with input from pediatric ICU and nephrology teams to prioritize safety and simplicity [9]